{
    "doi": "https://doi.org/10.1182/blood.V120.21.2115.2115",
    "article_title": "A Monocentric, Prospective, Observational Study On Vaso-Occlusive Crisis (VOC) in Adult Sickle-Cell Disease (SCD). ",
    "article_date": "November 16, 2012",
    "session_type": "111. Hemoglobinopathies, excluding Thalassemia: Poster II",
    "abstract_text": "Abstract 2115 Introduction VOC, the most common manifestation of SCD, is the first cause of death, particularly when complicated by an acute chest syndrome (ACS) or multiorgan failure. 1,2 Vichinsky et al 3 found that nearly half their patients included for ACS were initially hospitalized for VOC. However, no data are available on follow-up differences between patients hospitalized for uncomplicated VOC and those who will develop ACS. We report the preliminary analytical results of blood samples drawn on days 1, 2 and 4 of hospitalization for VOC and at steady state from patients enrolled in the more comprehensive PRESEV study. Methods This prospective, monocenter, observational trial included homozygous SCD patients, \u226518 years old with severe VOC requiring admission to our university hospital's Adult Sickle-Cell Referral Center. This study was conducted in accordance with the Declaration of Helsinki principles, Good Clinical Practice guidelines, and local laws and regulations. Severe VOC was defined as pain or tenderness, affecting at least 1 part of the body, e.g. limbs, ribs, sternum, head (skull), spine and/or pelvis, that required opioids and was not attributable to other causes. ACS was defined as the association of 2 criteria among chest pain, radiologic infiltrate and auscultatory abnormality. Patients could be enrolled in the trial more than once if their hospitalizations were separated by \u22651 months. Exclusion criteria were: ACS on day of inclusion, pregnancy, hospitalization for >24 h, chronic blood-exchange transfusion (BET), transfusion impossibility, severe complication requiring transfusion at admission, proven sepsis, surgery <15 days earlier. Patients were divided into 2 groups: VOC (without ACS) and those with secondary ACS; all were treated according to the French guidelines. 4 Steady state was defined as a consultation 3 1 months after an acute clinical event (VOC, infection, ACS, or any other clinical event requiring hospitalization and/or blood transfusion) and 3 3 months after last blood transfusion. Results are expressed as mean\u00b1SD. Results Among the 147 patients satisfying inclusion criteria: 38 (26%) developed an ACS on hospital day 3.2\u00b13; and 22 (15%) received acute BET or transfusion, including 18 with ACS (47% of ACS), 3 for prolonged VOC (including 1 with cytomegalovirus infection) and 1 for pure red-cell aplasia. For the VOC and ACS groups, respectively, mean ages were comparable (30.4\u00b17.2 and 30.6\u00b16.9 years), as were F/M sex ratios (0.7 and 0.8). No patient died. Their blood-parameter results are given in the Table  Parameter (n) . Day 1 . Day 2 . Day 4 . Steady state . P * . Time . VOC . ACS . VOC . ACS . VOC . ACS . VOC . ACS . Between groups . Hb g/dL (34/92) 9.1\u00b11.1 8.5\u00b11.3 9\u00b11.2 8.3\u00b11.3 8.9\u00b12.3 8\u00b11.4 9.4\u00b11.1 9.1\u00b11.2 0.004 <0.0001 Leukocytes/\u03bcL (32/90) 12749\u00b15089 14915\u00b14953 11644\u00b14255 16337\u00b112441 10006\u00b13781 13863\u00b15540 9503\u00b12471 9139\u00b12858 0.0005 <0.0001 Platelets 10 9 /L (33/91) 342\u00b1141 381\u00b1119 331\u00b1137 348\u00b1111 340\u00b1158 326\u00b1117 372\u00b1131 457\u00b1240 NS <0.0001 LDH UI/L (32/72) 447\u00b1201 568\u00b1202 451\u00b1221 672\u00b1395 398\u00b1144 572\u00b1315 375\u00b1162 398\u00b1187 0.0005 <0.0001 Bili T \u03bcmol/L (32/92) 49\u00b141 59\u00b136 47\u00b137 77\u00b176 39\u00b131 57\u00b144 52\u00b141 50\u00b131 0.07 0.0004 Bili D \u03bcmol/L (31/92) 10\u00b14 15\u00b19 11\u00b15 24\u00b137 10\u00b17 22\u00b121 9\u00b13 10\u00b13 <0.0001 <0.0001 GGT UI/L (31/88) 61\u00b157 74\u00b169 65\u00b161 83\u00b171 79\u00b173 103\u00b177 57\u00b154 81\u00b171 NS <0.0001 Creatinine \u03bcmol/L (33/92) 60\u00b115 60\u00b115 59\u00b116 58\u00b115 61\u00b117 55\u00b115 59\u00b116 54\u00b114 NS NS CPK UI/L (22/68) 80\u00b159 150\u00b1207 68\u00b153 109\u00b1113 58\u00b174 52\u00b150 93\u00b174 94\u00b178 0.08 <0.0001 Parameter (n) . Day 1 . Day 2 . Day 4 . Steady state . P * . Time . VOC . ACS . VOC . ACS . VOC . ACS . VOC . ACS . Between groups . Hb g/dL (34/92) 9.1\u00b11.1 8.5\u00b11.3 9\u00b11.2 8.3\u00b11.3 8.9\u00b12.3 8\u00b11.4 9.4\u00b11.1 9.1\u00b11.2 0.004 <0.0001 Leukocytes/\u03bcL (32/90) 12749\u00b15089 14915\u00b14953 11644\u00b14255 16337\u00b112441 10006\u00b13781 13863\u00b15540 9503\u00b12471 9139\u00b12858 0.0005 <0.0001 Platelets 10 9 /L (33/91) 342\u00b1141 381\u00b1119 331\u00b1137 348\u00b1111 340\u00b1158 326\u00b1117 372\u00b1131 457\u00b1240 NS <0.0001 LDH UI/L (32/72) 447\u00b1201 568\u00b1202 451\u00b1221 672\u00b1395 398\u00b1144 572\u00b1315 375\u00b1162 398\u00b1187 0.0005 <0.0001 Bili T \u03bcmol/L (32/92) 49\u00b141 59\u00b136 47\u00b137 77\u00b176 39\u00b131 57\u00b144 52\u00b141 50\u00b131 0.07 0.0004 Bili D \u03bcmol/L (31/92) 10\u00b14 15\u00b19 11\u00b15 24\u00b137 10\u00b17 22\u00b121 9\u00b13 10\u00b13 <0.0001 <0.0001 GGT UI/L (31/88) 61\u00b157 74\u00b169 65\u00b161 83\u00b171 79\u00b173 103\u00b177 57\u00b154 81\u00b171 NS <0.0001 Creatinine \u03bcmol/L (33/92) 60\u00b115 60\u00b115 59\u00b116 58\u00b115 61\u00b117 55\u00b115 59\u00b116 54\u00b114 NS NS CPK UI/L (22/68) 80\u00b159 150\u00b1207 68\u00b153 109\u00b1113 58\u00b174 52\u00b150 93\u00b174 94\u00b178 0.08 <0.0001 View Large Bili Tand D: total and direct bilirubinemia; GGT, Gamma- glutamyl transpeptidase; CPK: creatinine phosphokinase. *ANOVA for repeated measures: difference between VOC and ACS curves, and evolution over time. Conclusion These trial results provide new insights into very early evolution blood values for SCD patients hospitalized for VOC and those among them developing ACS, as compared to their steady-state values. It confirms the different evolutions in hemoglobin, leukocytes and LDH between VOC and secondary ACS, and shows muscle and liver involvement. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "acute chest syndrome",
        "blood platelets",
        "blood transfusion",
        "chest pain",
        "cranium",
        "creatinine",
        "cytomegalovirus",
        "drepanocytes",
        "follow-up",
        "gamma-glutamyl transferase"
    ],
    "author_names": [
        "Pablo Bartolucci, MD, PhD",
        "Anoosha Habibi",
        "Mehdi Khellaf",
        "Anne sophie Lascaux",
        "Aline Santin",
        "Franc\u0327oise Roudot Thoraval",
        "Ste\u0301phane Moutereau",
        "He\u0301le\u0300ne Jouault",
        "Yves Levy, MD, PhD",
        "Bertrand Renaud",
        "Frederic Galacteros, MD PhD",
        "Bertrand Godeau, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Pablo Bartolucci, MD, PhD",
            "author_affiliations": [
                "Sickle Cell Disease Center, Ho\u0302pital Henri MONDOR. APHP. UPEC. INSERM U955, CRETEIL, France, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Anoosha Habibi",
            "author_affiliations": [
                "Sickle Cell Disease Center, Ho\u0302pital Henri MONDOR, CRETEIL, France, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mehdi Khellaf",
            "author_affiliations": [
                "service de me\u0301decine interne., CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anne sophie Lascaux",
            "author_affiliations": [
                "Immunologie clinique, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, France, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Aline Santin",
            "author_affiliations": [
                "Service d'accueil des urgences, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, France, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Franc\u0327oise Roudot Thoraval",
            "author_affiliations": [
                "statistics, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ste\u0301phane Moutereau",
            "author_affiliations": [
                "biochimie, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "He\u0301le\u0300ne Jouault",
            "author_affiliations": [
                "he\u0301matologie biologie, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yves Levy, MD, PhD",
            "author_affiliations": [
                "service d'immunologie clinique, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Bertrand Renaud",
            "author_affiliations": [
                "Service d'accueil des urgences, CHU Henri Mondor. APHP. UPEC, Cre\u0301teil, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Frederic Galacteros, MD PhD",
            "author_affiliations": [
                "Sickle Cell Disease Center, Ho\u0302pital Henri MONDOR, CRETEIL, France, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Bertrand Godeau, MD",
            "author_affiliations": [
                "Centre Hospitalier Universitaire, Ho\u0302pital Henri Mondor, Cre\u0301teil, France"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-21T18:41:54",
    "is_scraped": "1"
}